ORGANIC
LETTERS
2008
Vol. 10, No. 5
1001-1004
Enantioselective Total Synthesis of
Peloruside A: A Potent Microtubule
Stabilizer
Arun K. Ghosh,*,† Xiaoming Xu,† Jae-Hun Kim,‡ and Chun-Xiao Xu†
Departments of Chemistry and Medicinal Chemistry, Purdue UniVersity,
West Lafayette, Indiana 47907, and UniVersity of Illinois at Chicago,
Department of Chemistry, Chicago, Illinois 60607
Received December 22, 2007
ABSTRACT
An enantioselective total synthesis of (
+)-peloruside A (1) is described. Peloruside A (1) is a potent microtubule stabilizer with significant
clinical potential. The synthesis is convergent and involves the assembly of C1
−
C10 segment 2 and C11 C24 segment 3 by a novel aldol
−
protocol followed by Yamaguchi macrolactonization of the resulting seco-acid, selective methylation of hemi-ketal and removal of the protecting
groups to peloruside A.
Peloruside A (1), a 16-membered macrolide antitumor agent,
was first isolated by West and Northcote from the New
Zealand marine sponge, Mycale hentscheli.1 It has shown
potent antitumor activity against P388 murine leukemia cells
with an IC50 value of 10 ng/mL (10 nM). Peloruside A is a
microtubule stabilizing agent and arrests cells in the G2-M
phase.2 However, like laulimalide, it binds to the non-taxoid
site of tubulin and has shown a synergistic effect with taxol.3,4
Peloruside A represents a new class of antitumor agents with
significant clinical potential. The intriguing structure, very
low natural abundance, and clinical potential of peloruside
A has attracted an immense synthetic interest. Thus far, De
Brabander et al. and subsequently Taylor and co-workers
have achieved the total synthesis of peloruside A.5 Further-
more, a number of synthetic studies of peloruside A subunits
have been reported.6 Herein we report a convergent total
synthesis of (+)-peloruside A. The key steps involve efficient
assembly of C1-C10 segment and C11-C24 segment by a
novel reductive enolization followed by a stereoselective
aldol process, an efficient Yamaguchi macrolactonization,
Z-selective olefination, Sharpless asymmetric dihydroxyla-
tion, and Brown’s asymmetric allylation reactions.
As shown in Figure 1, our synthetic strategy involves the
assembly of fragments 2 and 3 by a stereoselective aldol
reaction, followed by a macrolactonization of the corre-
(5) (a) Liao, X.; Wu, Y.; De Brabander, J. K. Angew. Chem., Int. Ed.
2003, 42, 1648. (b) Jin, M.; Taylor, R. E. Org. Lett. 2005, 7, 1303.
(6) (a) Paterson, I.; Di Francesco, M. E.; Kuhn, T. Org. Lett. 2003, 5,
599. (b) Ghosh, A. K.; Kim, J.-H. Tetrahedron Lett. 2003, 44, 3967. (c)
Ghosh, A. K.; Kim, J.-H. Tetrahedron Lett. 2003, 44, 7659. (d) Liu, B.;
Zhou, W. S. Org. Lett. 2004, 6, 71. (e) Owen, R. M.; Roush, W. R. Org.
Lett. 2005, 7, 3941. (f) Chen, Z.-L.; Zhou, W. S. Tetrahedron Lett. 2006,
47, 5289. (g) Roulland, E.; Ermolenko, M. S. Org. Lett. 2005, 7, 2225. (h)
Engers, D. W.; Bassindale, M. J.; Pagenkopf, B. L. Org. Lett. 2004, 6,
663. (i) Gurjar, M. K.; Pedduri, Y.; Ramana, C. V.; Puranik, V. G.; Gonnade,
R. G. Tetrahedron Lett. 2004, 45, 387. (j) Taylor, R. E.; Jin, M. Org. Lett.
2003, 5, 4959.
† Purdue University.
‡ University of Illinois at Chicago.
(1) West, L. M.; Northcote, P. T.; Battershill, C. N. J. Org. Chem. 2000,
65, 445.
(2) Hood, K. A.; West, L. M.; Rouwe, B.; Northcote, P. T.; Berridge,
M. V.; Wakefield, S. J.; Miller, J. H. Cancer Res. 2002, 62, 3356.
(3) Pryor, D. E.; O’Brate, A.; Bilcer, G.; Diaz, J. F.; Wang, Y.; Wang,
Y.; Kabaki, M.; Jung, M. K.; Andreu, J. M.; Ghosh, A. K.; Giannakakou,
P.; Hamel, E. Biochemistry 2002, 41, 9109.
(4) Gaitanos, T. N.; Buey, R. M.; Diaz, J. F.; Northcote, P. T.; Teesdale-
Spittle, P.; Andreu, J. M.; Miller, J. H. Cancer Res. 2004, 64, 5063.
10.1021/ol703091b CCC: $40.75
© 2008 American Chemical Society
Published on Web 02/05/2008